2023 World Conference on Lung Cancer (Posters)-EP12.01. Liquid Biopsy Reduce Time to Treatment for Patients with EGFR mutated Advanced Nonsquamous Non-small Cell Lung Cancer : A Mexican Unit Experience

EP12.01. Liquid Biopsy Reduce Time to Treatment for Patients with EGFR mutated Advanced Nonsquamous Non-small Cell Lung Cancer : A Mexican Unit Experience - PDF(Slides)

Back to course

Pdf Summary

Liquid biopsy is an effective and minimally invasive diagnostic method that can detect genetic alterations in tumors, such as EGFR mutations, without the need for a tissue biopsy. This study focused on the use of liquid biopsy for EGFR detection in a Thoracic Cancer Unit in Mexico. <br /><br />The study analyzed 100 patients with advanced non-small cell lung cancer (NSCLC) and found that 22% of patients had a positive plasma EGFR mutation. The majority of these mutations were found in exon 19. The median test timing for liquid biopsy was significantly shorter compared to tissue PCR, allowing for quicker results. <br /><br />Liquid biopsy led to the use of EGFR inhibitors in 91% of patients with positive mutations. The concordance between plasma and tissue evaluation was 90%. <br /><br />Overall, liquid biopsy is a valuable tool for diagnosing and monitoring EGFR-mutated advanced NSCLC. It has the potential to reduce the time to treatment, allowing patients to receive timely and effective treatment. This can greatly impact patient outcomes, particularly for those with advanced disease where time is critical. Implementing liquid biopsy in clinical practice can improve the management of EGFR-mutated NSCLC and contribute to better patient outcomes.

Asset Subtitle

Saul Campos-Gomez

Meta Tag

Speaker Saul Campos-Gomez

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

Liquid biopsy

diagnostic method

EGFR mutations

non-small cell lung cancer

plasma EGFR mutation

exon 19

tissue PCR

EGFR inhibitors

advanced NSCLC

patient outcomes